The prevention of RPS is the most important goal of all therapies for childhood UTI, and if APOL1 kidney risk variants are shown to be associated with RPS, it will offer less invasive genetic biomarkers for predicting children who will develop RPS following UTI. The gene discussed is APOL1; the disease is bacterial urinary tract infection.